Patents Examined by Bao Q Li
  • Patent number: 10413603
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 17, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Robert L. Garcea, Dennis G. Macejak
  • Patent number: 10414802
    Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 17, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Claudio Ciferri, Irmgard Hofmann, Holger Laux, Anders Lilja, Yingxia Wen
  • Patent number: 10415106
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of a human papillomavirus (HPV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: September 17, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventor: Astrid R. W. Schroder
  • Patent number: 10406185
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 10, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Antonio Marchini, Junwei Li, Lea Schroeder, Jean Rommelaere, Karsten Geletneky
  • Patent number: 10392656
    Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 27, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: James D. Carlson, Steven T. Brentano
  • Patent number: 10385101
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 20, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 10378069
    Abstract: The invention is directed to compositions, kits, and methods for amplifying and detecting a Zika virus nucleic acid sequence in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: August 13, 2019
    Assignee: Abbott Molecular Inc.
    Inventors: Matthew Frankel, George Schneider
  • Patent number: 10363304
    Abstract: The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion exchange chromatography and tangential flow filtration.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: July 30, 2019
    Assignee: SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Sophia Mundle, Stephen Anderson, Simon Delagrave
  • Patent number: 10358472
    Abstract: High affinity CD47 reagents are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for a SIRP? relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity CD47 reagent, which blocks the physiological binding interaction between SIRP? and a ligand, e.g., native CD47.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: July 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chia Chi Ho, Kenan Christopher Garcia, Aaron Michael Ring, Kipp Andrew Weiskopf, Irving L. Weissman, Nan Guo Ring
  • Patent number: 10350286
    Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 16, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
  • Patent number: 10335478
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: July 2, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol University
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Patent number: 10329539
    Abstract: The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: THE CHARLES STARK DRAPER LABORATORY INC.
    Inventors: Connor McBrine, Georgiana Kourepenos, Parker Dow, Jason Holder
  • Patent number: 10329330
    Abstract: The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair is formed by an amino acid of the first interaction region and an amino acid of the second interaction region, —the interaction between the amino acids of an interaction pair is covalent or non-covalent; and —at least one interaction pair is a covalent interaction pair in which the amino acids are covalently bound, and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: June 25, 2019
    Assignee: LIFE SCIENCE INKUBATOR GMBH
    Inventors: Sebastian Franken, Alexander Glassmann, Nadine Temme
  • Patent number: 10316094
    Abstract: Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 11, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roy Louis Maute, Kipp Andrew Weiskopf, Aaron Michael Ring, Irving L. Weissman
  • Patent number: 10300130
    Abstract: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 28, 2019
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Patent number: 10301600
    Abstract: The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 28, 2019
    Assignee: BioVex Limited
    Inventor: Robert S. Coffin
  • Patent number: 10300128
    Abstract: The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) comprising nucleoproteins of a non-segmented negative-strand ribonucleic acid (RNA) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric RNPs resulting from the assembly of at least 200 fusion proteins with a cellular RNA, or to recombinant yeasts or yeast lysates expressing these multimeric RNPs. It also concerns a process for the preparation of these multimeric RNPs or recombinant yeasts or yeast lysates. In particular, the present invention relates to their use as active ingredient for the in vitro production of an immunogenic composition or in eliciting a protective prophylactic or a therapeutic immune response against said heterologous polypeptide in a host in need thereof. Recombinant yeasts or yeast lysates of the invention can also be used as expression and vector systems for delivery to a host.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 28, 2019
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Monica Sala, Daria Jacob, Frederic Tangy
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 10233484
    Abstract: Disclosed herein are methods and systems for detection of a microorganism of interest using an amplification assay. The methods and systems utilize the specificity of binding agents, such as antibodies, to rapidly detect low levels of a specific microorganism present in a sample. In certain embodiments, antibodies are bound to a large number of the available binding sites on a microorganism.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Dwight Lyman Anderson, Ben Barrett Hopkins, Jose S. Gil, Stephen Erickson, Ekaterina Kovacheva
  • Patent number: 10232003
    Abstract: The present invention relates to exogenous TAP inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade CD8+ cytolytic T-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting TAP. The viruses of the invention also comprise one or more heterologous genes encoding immunomodulatory polypeptides, prodrug converting enzymes, or matrix degrading enzymes. Compositions and therapeutic methods using the oncolytic viruses are also provided, including compositions and therapeutic methods for treating cancers, such as melanoma, head and neck cancer, ovarian cancer, breast cancer, glioblastoma, bladder cancer, prostate cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, and renal cancer.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 19, 2019
    Assignee: BeneVir Biopharm, Inc.
    Inventors: Matthew Mulvey, Steven Fuhrmann, Ram Aiyar